Market Closed -
Nasdaq
04:00:00 2024-07-02 pm EDT
|
5-day change
|
1st Jan Change
|
18.26
USD
|
-4.00%
|
|
-5.63%
|
-13.99%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,951
|
2,507
|
2,346
|
1,560
|
1,292
|
1,126
|
-
|
-
|
Enterprise Value (EV)
1 |
1,421
|
1,904
|
2,012
|
933.5
|
553.1
|
1,126
|
1,126
|
1,126
|
P/E ratio
|
74.8
x
|
-36.1
x
|
29.3
x
|
-28
x
|
-10.2
x
|
-5.19
x
|
-6.89
x
|
-10.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
12.4
x
|
20.4
x
|
8.53
x
|
9.48
x
|
7.68
x
|
14
x
|
7.71
x
|
4.68
x
|
EV / Revenue
|
12.4
x
|
20.4
x
|
8.53
x
|
9.48
x
|
7.68
x
|
14
x
|
7.71
x
|
4.68
x
|
EV / EBITDA
|
108
x
|
-35.3
x
|
45.8
x
|
-21.2
x
|
-10.2
x
|
-5.62
x
|
-6.7
x
|
-9.51
x
|
EV / FCF
|
34.2
x
|
-161
x
|
-77.8
x
|
-111
x
|
19.4
x
|
-7.13
x
|
-8.25
x
|
-12.2
x
|
FCF Yield
|
2.92%
|
-0.62%
|
-1.29%
|
-0.9%
|
5.16%
|
-14%
|
-12.1%
|
-8.17%
|
Price to Book
|
3.3
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
56,721
|
57,455
|
58,482
|
59,924
|
60,875
|
61,663
|
-
|
-
|
Reference price
2 |
34.39
|
43.63
|
40.12
|
26.04
|
21.23
|
18.26
|
18.26
|
18.26
|
Announcement Date
|
2/24/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
156.7
|
122.7
|
275.1
|
164.6
|
168.3
|
80.59
|
146.1
|
240.4
|
EBITDA
1 |
18.12
|
-71
|
51.26
|
-73.67
|
-127.1
|
-200.3
|
-168
|
-118.4
|
EBIT
1 |
13.82
|
-76.8
|
43.77
|
-82.47
|
-138.6
|
-220.3
|
-182.6
|
-109.1
|
Operating Margin
|
8.82%
|
-62.59%
|
15.91%
|
-50.11%
|
-82.36%
|
-273.37%
|
-124.97%
|
-45.38%
|
Earnings before Tax (EBT)
1 |
27.19
|
-69.33
|
82.63
|
-54.51
|
-120.4
|
-208.4
|
-154.4
|
-102.8
|
Net income
1 |
26.88
|
-69.33
|
82.63
|
-55.18
|
-126.1
|
-215.9
|
-165.5
|
-109.9
|
Net margin
|
17.15%
|
-56.51%
|
30.04%
|
-33.53%
|
-74.9%
|
-267.9%
|
-113.31%
|
-45.69%
|
EPS
2 |
0.4600
|
-1.210
|
1.370
|
-0.9300
|
-2.080
|
-3.515
|
-2.651
|
-1.726
|
Free Cash Flow
1 |
57.02
|
-15.54
|
-30.15
|
-14.01
|
66.66
|
-158
|
-136.5
|
-92
|
FCF margin
|
36.39%
|
-12.67%
|
-10.96%
|
-8.51%
|
39.6%
|
-196.05%
|
-93.44%
|
-38.26%
|
FCF Conversion (EBITDA)
|
314.65%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
212.17%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
154
|
85.5
|
30.18
|
27.3
|
21.61
|
18.96
|
45.52
|
59.16
|
44.69
|
12.8
|
21.03
|
21.22
|
23
|
22.29
|
22.54
|
EBITDA
1 |
93.76
|
28.64
|
-25.78
|
-36.11
|
-40.43
|
-57.12
|
-23.11
|
-15.13
|
-30.4
|
-54.82
|
-19.53
|
-19.85
|
-20.93
|
-21.88
|
-22.03
|
EBIT
1 |
91.65
|
26.47
|
-28
|
-38.35
|
-42.59
|
-59.36
|
-26
|
-18.27
|
-33.63
|
-57.86
|
-52.93
|
-52.65
|
-52.22
|
-48.07
|
-49.65
|
Operating Margin
|
59.51%
|
30.96%
|
-92.79%
|
-140.47%
|
-197.1%
|
-313.07%
|
-57.11%
|
-30.88%
|
-75.25%
|
-451.82%
|
-251.66%
|
-248.08%
|
-227.07%
|
-215.68%
|
-220.31%
|
Earnings before Tax (EBT)
1 |
73.06
|
23.59
|
-33.98
|
-31.67
|
-12.46
|
-60.76
|
-21.95
|
-24.27
|
-13.45
|
-68.71
|
-48.01
|
-47.71
|
-46.25
|
-46.24
|
-47.99
|
Net income
1 |
73.06
|
23.59
|
-33.98
|
-32.76
|
-12.04
|
-60.76
|
-21.95
|
-24.27
|
-19.1
|
-68.03
|
-49.82
|
-49.48
|
-48.09
|
-46.24
|
-47.99
|
Net margin
|
47.44%
|
27.6%
|
-112.59%
|
-120%
|
-55.72%
|
-320.45%
|
-48.23%
|
-41.02%
|
-42.74%
|
-531.3%
|
-236.86%
|
-233.15%
|
-209.12%
|
-207.45%
|
-212.91%
|
EPS
2 |
1.210
|
0.3900
|
-0.5700
|
-0.5500
|
-0.2000
|
-1.020
|
-0.3700
|
-0.4000
|
-0.3100
|
-1.110
|
-0.8106
|
-0.8042
|
-0.7772
|
-0.8267
|
-0.8433
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/23/22
|
5/5/22
|
8/3/22
|
11/7/22
|
2/23/23
|
5/8/23
|
8/3/23
|
11/7/23
|
2/27/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
530
|
603
|
334
|
627
|
739
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
57
|
-15.5
|
-30.2
|
-14
|
66.7
|
-158
|
-137
|
-92
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-7.55%
|
-18.1%
|
-35%
|
-43.4%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-6.55%
|
-14%
|
-26.7%
|
-27.5%
|
-
|
Assets
1 |
-
|
-
|
-
|
842.2
|
899.5
|
807.8
|
601.1
|
-
|
Book Value Per Share
|
10.40
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
1.100
|
-
|
-
|
-
|
1.410
|
-4.970
|
-1.040
|
-
|
Capex
1 |
7.35
|
10.5
|
13.3
|
38.5
|
18.4
|
9.93
|
9.93
|
8.4
|
Capex / Sales
|
4.69%
|
8.59%
|
4.83%
|
23.39%
|
10.96%
|
12.33%
|
6.8%
|
3.49%
|
Announcement Date
|
2/24/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
18.26
USD Average target price
33.83
USD Spread / Average Target +85.29% Consensus |
1st Jan change
|
Capi.
|
---|
| -13.99% | 1.13B | | +16.44% | 122B | | +18.94% | 113B | | +18.63% | 26.22B | | -25.37% | 19.01B | | -20.49% | 15.71B | | -20.20% | 15.22B | | -47.37% | 14.72B | | +59.91% | 14.58B | | +4.35% | 13.84B |
Bio Therapeutic Drugs
|